29106 Federal Register / Vol. 61, No. 111 / Friday, June 7, 1996 / Notices

For the Department of Agriculture of the

United States of America: and Certification:

/s/ Richard E. Rominger

January 30, 1996

Washington, D.C.

For the Food and Drug Administration of the

United States of America:

/s/ Mary Pendergast

January 30, 1996

Washington, D.C.

For the State Committee for Sanitary and

Epidemiological Surveillance of the Russian

Federation:

/s/ G. G. Onitshenko

January 30, 1996

Washington, D.C.

For the Committee of the Russian Federation

on Standardization, Metrology, and

Certification:

/s/ S. Bezverkhi

March 29, 1996

Moscow, Russian Federation

[FR Doc. 96–14387Filed 6–06–96; 8:45 am]

BILLING CODE 4160–01–F

National Institutes of Health

Prostate, Lung, Colorectal and Ovarian

Cancer Screening Trial; Proposed

Collection; Comment Request;

SUMMARY: In compliance with the

requirement of Section 3506(c)(2)(A) of

the Paperwork Reduction Act of 1995,

for opportunity for public comment on

proposed data collection projects, the

National Cancer Institute (NCI), the

National Institutes of Health (NIH) will

publish periodic summaries of proposed

projects to be submitted to the Office of

Management and Budget (OMB) for

review and approval.

PROPOSED COLLECTION: Title: Prostate,

Lung, Colorectal and Ovarian Cancer

Screening Trial. Type of Information

Collection Request: EXTENSION, OMB

control number 0925–0407, expiration

date September 30, 1996. Need and Use

of Information Collection: This trial is

designed to determine if screening for

prostate, lung, colorectal and ovarian

cancer can reduce mortality from these

cancers which currently cause an

estimated 251,000 deaths annually in

the U.S. The design is a two-armed

randomized trial of men and women

aged 55 to 74 at entry. The anticipated

total sample size, after four and one half

years of recruitment, is projected to be

148,000. The primary endpoint of the

trial is cancer-specific mortality for each

of the four cancer sites (prostate, lung,

colorectal, and ovary). In addition,

cancer incidence, stage shift, and case

survival are to be monitored to help

understand and explain results. Biologic

prognostic characteristics of the cancers

will be measured and correlated with

mortality to determine the mortality

predictive value of these intermediate

endpoints. Basic demographic data, risk

factor data for the four cancer sites and

screening history data, as collected from

all subjects at baseline, will be used to

assure comparability between the

screening and control groups and make

appropriate adjustments in analysis.

Further, demographic and risk factor

information will be used to analyze the

differential effectiveness of screening in

high versus low risk individuals.

Frequency of Response: On occasion.

Affected Public: Individuals or

households. Type of Respondents: Adult

men and women. The annual reporting

burden is as follows: Estimated Number

of Respondents: 75,333; Estimated

Number of Responses per Respondent:

1.7; Average Burden Hours Per

Response: .573; and Estimated Total

Annual Burden Hours Requested:

73,400. The annualized cost to

respondents is estimated at: $734,290.

There are no Capital Costs to report.

There are no Operating or Maintenance

Costs to report.

REQUEST FOR COMMENTS: Written

comments and/or suggestions from the

public and affected agencies should

address one or more of the following

points: (1) Evaluate whether the

proposed collection of information is

necessary for the proper performance of

the function of the agency, including

whether the information will have

practical utility; (2) Evaluate the

accuracy of the agency’s estimate of the

burden of the proposed collection of

information, including the validity of

the methodology and assumptions used;

(3) Enhance the quality, utility, and

clarity of the information to be

collected; and (4) Minimize the burden

of the collection of information on those

who are to respond, including the use

of appropriate automated, electronic,

mechanical, or other technological

collection techniques or other forms of

information technology.

FOR FURTHER INFORMATION CONTACT:

To request more information on the

proposed project or to obtain a copy of

the data collection plans and

instruments, contact Dr. John Gohagan,

Chief, Early Detection Branch, EDCOP,

National Cancer Institute, NIH, EPN

Building, Room 330, 6130 Executive

Boulevard, Bethesda, MD 20892–7346,

or call non-toll-free number (301) 496–

3982 or E-mail your request, including

your address to:

gohaganj@dcpcepn.nci.nih.gov

COMMENTS DUE DATE: Comments

regarding this information collection are

best assured of having their full effect if

received within 60-days of the date of

this publication.

Dated: May 30, 1996.

Philip D. Amoruso,

Executive Officer, NCI.

[FR Doc. 96–14431 Filed 6–6–96; 8:45 am]

BILLING CODE 4140–01–M

National Center for Human Genome

Research; Notice of Closed Meetings

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix), notice is

hereby given of the following meetings

of the National Center for Human

Genome Research Special Emphasis

Panel:

Agenda/Purpose: To review and evaluate

grant applications and/or contract proposals.

Name of Committee: National Center for

Human Genome Research Special Emphasis

Panel 01.

Date: June 24, 1996.

Time: 7:00 p.m.

Place: NIH, Natcher (Building 45), Rooms

G1/G2, 9000 Rockville Pike, Bethesda,

Maryland

Contact Person: Ms. Linda Engel, Chief,

Office of Scientific Review, National Center

for Human Genome Research, National

Institutes of Health, Building 38A, Room 604,

Bethesda, Maryland 20892, (301) 402–0838.

Name of Committee: National Center for

Human Genome Research Special Emphasis

Panel 02.

Date: June 25, 1996.

Time: 9:00 a.m.

Place: NIH, Natcher (Building 45), Rooms

G1/G2, 9000 Rockville Pike, Bethesda,

Maryland.

Contact Person: Ms. Linda Engel, Chief,

Office of Scientific Review, National Center

for Human Genome Research, National

Institutes of Health, Building 38A, Room 604,

Bethesda, Maryland 20892, (301) 402–0838.

Name of Committee: National Center for

Human Genome Research Special Emphasis

Panel 03.

Date: June 25, 1996.

Time: 9:00 a.m.

Place: NIH, Natcher (Building 45), Rooms

F1/F2, 9000 Rockville Pike, Bethesda,

Maryland.

Contact Person: Ms. Linda Engel, Chief,

Office of Scientific Review, National Center

for Human Genome Research, National

Institutes of Health, Building 38A, Room 604,

Bethesda, Maryland 20892, (301) 402–0838.

The meetings will be closed in accordance

with the provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5, U.S.C. The

applications and/or contract proposals, and

the discussions could reveal confidential

trade secrets or commercial property such as

patentable material, and personal

information concerning individuals

associated with applications, the disclosure

of which would constitute a clearly

unwarranted invasion of personal privacy.